NEW YORK, Feb. 16 /PRNewswire-FirstCall/ -- Bioaccelerate Holdings Inc. (BACL.OB), a company that acquires and invests in the development of pharmaceutical compounds, announced today its sponsorship of the annual Milken Institute Global Conference, taking place April 18-April 20, 2005 at the Beverly Hilton Hotel in Los Angeles, CA. The conference draws together more than 2,000 senior decision makers from industry, government, financial institutions, and philanthropy from over 50 countries to discuss and debate ideas about how to solve some of the world’s most pressing challenges.
“Bioaccelerate is delighted to be a major sponsor of this important annual event for the second year in a row,” stated Frank Armstrong, M.D., Chief Operating Officer of Bioaccelerate. “Among the topics to be discussed at this year’s conference will be university-based biotechnology research, development and commercialization. In a panel discussion to be led by Bioaccelerate, prominent experts from academia and the pharmaceutical industry will explore ways to help facilitate more efficient technology transfer so that promising new medicines can be brought to market more quickly and cost effectively.”
This year’s conference, “Building a Prosperous Future,” will examine such issues as biotechnology and the promise of medical breakthroughs; the global investment climate; and the latest economic developments in Europe, Asia, Russia, Latin America and the U.S.
Among confirmed speakers at the conference are former Vice President Al Gore; Rupert Murdoch, Chairman and CEO, News Corporation; Terry Semel, Chairman and CEO, Yahoo!; Charlene Barshefsky, former U.S. Trade Representative; Mel Karmazin, CEO, SIRIUS Satellite Radio; Steve Forbes, President and CEO, Forbes; William Haseltine, former CEO, Human Genome Sciences; Douglas Holtz-Eakin, Director, Congressional Budget Office; Jonathan Miller, Chairman and CEO, AOL; Mike Milken, Chairman of FasterCures and the Milken Institute; Steve Wynn, President and CEO, Wynn Resorts; Sam Zell, Chairman, Equity Group Investments; and more than 200 others.
For complete information about the 2005 Global Conference, go to: http://www.milkeninstitute.org/gc2005.
About Bioaccelerate Holdings Inc.
Bioaccelerate Holdings Inc. is a pharmaceutical development organization that seeks to acquire, develop and commercialize novel pharmaceutical compounds in an efficient, cost-effective way for the benefit patients and its shareholders. Bioaccelerate uses its broad network of academic, industry and capital market relationships to expedite drug development and raise capital to create and fund its subsidiary companies, which are organized by vertical portfolios in five therapeutic areas: oncology, specialty pharmaceuticals, central nervous system disorders (CNS), cardiovascular disease and anti-infectives.
Bioaccelerate conducts its business directly and through its subsidiaries. The company holds majority equity interests in ten biopharmaceutical companies (three of which are public) and holds minority interests in four biopharmaceutical companies (two of which are public). The company also holds a minority equity interest in a public nanotechnology company.
Bioaccelerate’s strategy relies on its development network for research, clinical development and project management to guide early-stage compounds from the discovery process through to Phase II/III development where incremental value can be created. Bioaccelerate Holdings is quoted on the Over-The-Counter Bulletin Board under the symbol “BACL.OB.” For more information on Bioaccelerate, visit the company’s website at http://www.bioaccelerate.com/.
Bioaccelerate Safe Harbor Statement
Certain statements contained herein are “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to: risks associated with pre-clinical and clinical developments in the biopharmaceutical industry in general and in Bioaccelerate’s compounds under development in particular; the potential failure of Bioaccelerate’s compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Bioaccelerate’s compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Bioaccelerate’s business, structure or projections; the development of competing products; uncertainties related to Bioaccelerate’s dependence on third parties and partners. Bioaccelerate disclaims any obligation to update these forward-looking statements.
About the Milken Institute
The Milken Institute is a nonprofit, independent economic think tank whose mission is to improve the lives and economic conditions of diverse populations around the world by helping business and public policy leaders identify and implement innovative ideas for creating broad-based prosperity. It is based in Santa Monica, CA. (http://www.milkeninstitute.org/)
Contact: Bioaccelerate Holdings Inc. Christopher O’Toole Senior Vice President 212-897-6849 Matthew Haines (Investors) Vice President Noonan Russo 212-845-4235 Emily Poe (Media) Vice President Noonan Russo 212-845-4266
Bioaccelerate Holdings Inc.
CONTACT: Christopher O’Toole, Senior Vice President of BioaccelerateHoldings Inc., +1-212-897-6849; or Matthew Haines (Investors), Vice President,+1-212-845-4235, or Emily Poe (Media), Vice President, +1-212-845-4266, bothof Noonan Russo, for Bioaccelerate Holdings Inc.
